MCID: CHL061
MIFTS: 55

Childhood Leukemia

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Childhood Leukemia

MalaCards integrated aliases for Childhood Leukemia:

Name: Childhood Leukemia 12 43 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:7757
NCIt 50 C4989
UMLS 73 C1332977

Summaries for Childhood Leukemia

MedlinePlus : 43 Leukemia is cancer of the white blood cells. It is the most common type of childhood cancer. Your blood cells form in your bone marrow. White blood cells help your body fight infection. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. Leukemia can develop quickly or slowly. Acute leukemia is a fast growing type while chronic leukemia grows slowly. Children with leukemia usually have one of the acute types. Symptoms include Infections Fever Loss of appetite Tiredness Easy bruising or bleeding Swollen lymph nodes Night sweats Shortness of breath Pain in the bones or joints Risk factors for childhood leukemia include having a brother or sister with leukemia, having certain genetic disorders and having had radiation or chemotherapy. Treatment often cures childhood leukemia. Treatment options include chemotherapy, other drug therapy and radiation. In some cases bone marrow and blood stem cell transplantation might help. NIH: National Cancer Institute

MalaCards based summary : Childhood Leukemia is related to leukemia, acute lymphoblastic and leukemia, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Childhood Leukemia is TCF3 (Transcription Factor 3), and among its related pathways/superpathways are NF-kappaB Signaling and Transcriptional misregulation in cancer. The drugs Elliotts B Solution and Teniposide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and b cells, and related phenotypes are Reduced mammosphere formation and growth/size/body region

Disease Ontology : 12 A leukemia that occurs in children.

Wikipedia : 76 Childhood leukemia is a type of leukemia, usually acute lymphocytic leukemia (ALL), and a type of... more...

Related Diseases for Childhood Leukemia

Diseases related to Childhood Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute lymphoblastic 30.8 ETV6 KMT2A RUNX1
2 leukemia 30.4 ETV6 MLLT3 PBX1 PTPN11 RUNX1 TP53
3 acute lymphocytic leukemia 29.7 ETV6 MTHFR RUNX1 TP53
4 myeloid leukemia 29.2 ETV6 PTPN11 RUNX1 TP53
5 lymphoblastic leukemia 28.7 ARID5B CYP1A1 ETV6 MLLT1 PBX1 PTPN11
6 acute leukemia 28.5 ETV6 KMT2A MLLT1 MLLT3 MTHFR RUNX1
7 leukemia, acute myeloid 27.7 ETV6 KMT2A MLLT1 MLLT3 PTPN11 RUNX1
8 pediatric t-cell leukemia 10.9
9 ring chromosome 21 10.7 ETV6 KMT2A
10 platelet disorder, familial, with associated myeloid malignancy 10.7 ETV6 RUNX1
11 b-cell childhood acute lymphoblastic leukemia 10.7 ETV6 RUNX1
12 acute lymphoblastic leukemia, childhood 10.5 ETV6 MTHFR RUNX1
13 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.5 ETV6 KMT2A RUNX1
14 mn1 10.5 ETV6 KMT2A
15 acute myeloid leukemia with t(9;11)(p22;q23) 10.5 KMT2A MLLT3
16 differentiated thyroid carcinoma 10.4 ETV6 MTHFR TP53
17 lymphoid leukemia 10.4 ETV6 KMT2A
18 lymphoma 10.2
19 breast adenocarcinoma 10.0 CYP1A1 NQO1 TP53
20 gastric adenosquamous carcinoma 10.0 TFRC TP53
21 aging 9.9
22 bone marrow cancer 9.9 ETV6 PTPN11 RUNX1
23 hematopoietic stem cell transplantation 9.9
24 hematologic cancer 9.8 ETV6 KMT2A PTPN11 RUNX1 TP53
25 leukemia, acute lymphoblastic 3 9.8 ETV6 KMT2A PBX1 RUNX1 TCF3 TP53
26 glucocorticoid resistance, generalized 9.7
27 arthritis 9.7
28 osteonecrosis 9.7
29 cerebritis 9.7
30 influenza 9.7
31 rheumatoid arthritis 9.6
32 down syndrome 9.6
33 hemochromatosis, type 1 9.6
34 lymphoma, hodgkin, classic 9.6
35 lymphoma, non-hodgkin, familial 9.6
36 brain cancer 9.6
37 juvenile rheumatoid arthritis 9.6
38 lymphosarcoma 9.6
39 cytomegalic inclusion disease 9.6
40 back pain 9.6
41 diabetes mellitus, noninsulin-dependent 9.5
42 multiple sclerosis 9.5
43 attention deficit-hyperactivity disorder 9.5
44 myositis 9.5
45 noonan syndrome 1 9.5
46 sturge-weber syndrome 9.5
47 ataxia-telangiectasia 9.5
48 combined immunodeficiency, x-linked 9.5
49 wilms tumor 5 9.5
50 meningioma, radiation-induced 9.5

Graphical network of the top 20 diseases related to Childhood Leukemia:



Diseases related to Childhood Leukemia

Symptoms & Phenotypes for Childhood Leukemia

UMLS symptoms related to Childhood Leukemia:


angina pectoris, chest pain, edema

GenomeRNAi Phenotypes related to Childhood Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.28 C1QC ETV6 HFE KMT2A NQO1 PTPN11

MGI Mouse Phenotypes related to Childhood Leukemia:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.4 PTPN11 TCF3 RUNX1 TP53 TFRC NQO1
2 hematopoietic system MP:0005397 10.39 TCF3 RUNX1 PTPN11 TP53 TFRC NQO1
3 homeostasis/metabolism MP:0005376 10.34 PTPN11 TCF3 PBX1 RUNX1 TP53 TFRC
4 immune system MP:0005387 10.32 PTPN11 TCF3 RUNX1 TP53 TFRC NQO1
5 cellular MP:0005384 10.31 PTPN11 TCF3 PBX1 RUNX1 TFRC TP53
6 mortality/aging MP:0010768 10.27 PTPN11 TCF3 RUNX1 TP53 TFRC CYP1A1
7 cardiovascular system MP:0005385 10.23 RUNX1 PTPN11 PBX1 TFRC TP53 ETV6
8 embryo MP:0005380 10.2 PTPN11 TCF3 PBX1 RUNX1 TP53 TFRC
9 endocrine/exocrine gland MP:0005379 10.19 PTPN11 TCF3 PBX1 RUNX1 TP53 ARID5B
10 digestive/alimentary MP:0005381 10.16 PTPN11 PBX1 TP53 TFRC ARID5B ETV6
11 integument MP:0010771 10.16 PTPN11 RUNX1 TP53 TFRC KMT2A NQO1
12 liver/biliary system MP:0005370 10.14 TCF3 RUNX1 PTPN11 TP53 TFRC NQO1
13 limbs/digits/tail MP:0005371 10.03 PTPN11 TCF3 TP53 KMT2A HFE PBX1
14 neoplasm MP:0002006 10.02 PTPN11 TCF3 RUNX1 TP53 NQO1 MLLT1
15 nervous system MP:0003631 9.96 RUNX1 PTPN11 TCF3 PBX1 TFRC TP53
16 no phenotypic analysis MP:0003012 9.9 TCF3 RUNX1 PTPN11 TP53 TFRC CYP1A1
17 normal MP:0002873 9.7 PTPN11 TCF3 RUNX1 TP53 TFRC KMT2A
18 reproductive system MP:0005389 9.28 PTPN11 TCF3 PBX1 TP53 ARID5B KMT2A

Drugs & Therapeutics for Childhood Leukemia

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Elliotts B Solution 18 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996

Drugs for Childhood Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 935)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Teniposide Approved Phase 4,Phase 3,Phase 2,Not Applicable 29767-20-2 34698
2
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
3
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 95058-81-4 60750
4
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
5
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
6
alemtuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216503-57-0
7
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
8
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
9
Menthol Approved Phase 4,Phase 2,Phase 1,Not Applicable 2216-51-5 16666
10
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
11
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
12
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302962-49-8 3062316
13
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
14
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 53910-25-1 40926 439693
15
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 3778-73-2 3690
16
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 191732-72-6 216326
17
Amsacrine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51264-14-3 2179
18
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137234-62-9 71616
19
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170729-80-3 151165 6918365
20
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
21
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 14956 5280965
22
Topotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 119413-54-6, 123948-87-8 60700
23
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
24
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
25
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 305-03-3 2708
26
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
27
Ketamine Approved, Vet_approved Phase 4,Phase 3 6740-88-1 3821
28
Acitretin Approved Phase 4 55079-83-9 6437841 5284513
29
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
30
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
31
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
32
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
33
Valproic Acid Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 99-66-1 3121
34
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
35
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
36
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
37
Palonosetron Approved, Investigational Phase 4,Phase 2,Not Applicable 135729-61-2, 119904-90-4, 135729-56-5 148211
38
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492
39
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
40
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
41
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
42
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20830-81-3 30323
43
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84625-61-6 55283
44
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
45
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 128794-94-5 5281078
46
Granisetron Approved, Investigational Phase 4,Phase 2,Not Applicable 109889-09-0 3510
47
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 58-61-7 60961
48
Cladribine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 4291-63-8 20279
49
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154-42-7 2723601
50
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741

Interventional clinical trials:

(show top 50) (show all 6293)
# Name Status NCT ID Phase Drugs
1 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia Unknown status NCT00180128 Phase 4 all-trans retinoid acid;idarubicin;mitoxantrone;daunorubicin;cytarabine
2 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
3 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
4 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
5 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
6 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
7 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
8 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
9 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
10 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
11 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
12 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
13 Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL Unknown status NCT01987297 Phase 4 ATRA+arsenic;ATRA+chemo
14 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
15 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
16 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
17 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
18 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
19 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
20 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
21 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
22 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
23 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
24 Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
25 Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived) Unknown status NCT02218437 Phase 4 MSC+ATG
26 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
27 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
28 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4 Nilotinib
29 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
30 Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
31 Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4 Arsenic Trioxide;ATRA
32 Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
33 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
34 Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Completed NCT00465933 Phase 4 AIDA
35 Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
36 Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia Completed NCT01819792 Phase 4
37 PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia Completed NCT00362544 Phase 4 Ambisome
38 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
39 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
40 Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Completed NCT00408278 Phase 4 ATRA;Idarubicina;Mitoxantrone;ARA-C
41 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
42 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4 nilotinib
43 Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
44 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
45 Antiviral Treatment of Chronic Lymphocytic Leukemia Completed NCT01255644 Phase 4 Valganciclovir
46 LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
47 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
48 A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status Completed NCT01283386 Phase 4 chlorambucil;cyclophosphamide;fludarabine;rituximab [MabThera]
49 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4 Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
50 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib

Search NIH Clinical Center for Childhood Leukemia

Genetic Tests for Childhood Leukemia

Anatomical Context for Childhood Leukemia

MalaCards organs/tissues related to Childhood Leukemia:

41
Myeloid, T Cells, B Cells, Bone, Bone Marrow, Lung, Breast

Publications for Childhood Leukemia

Articles related to Childhood Leukemia:

(show top 50) (show all 681)
# Title Authors Year
1
Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated With ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group. ( 29360413 )
2018
2
A greater birthweight increases the risk of acute leukemias in Mexican children-experience from the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia (MIGICCL). ( 29533016 )
2018
3
Long-term sequelae in survivors of childhood leukemia with Down syndrome: A childhood cancer survivor study report. ( 29105081 )
2018
4
dbLGL: an online leukemia gene and literature database for the retrospective comparison of adult and childhood leukemia genetics with literature evidence. ( 29961819 )
2018
5
Ambient benzene at the residence and risk for subtypes of childhood leukemia, lymphoma and CNS tumor. ( 29633247 )
2018
6
Influence of Nitrosative Stress on Fatigue During Childhood Leukemia Treatment. ( 29716390 )
2018
7
Prevalence and characteristics of metabolic syndrome in adults from the French childhood leukemia survivors' cohort: A comparison with controls from the French population. ( 29351982 )
2018
8
Residential mobility and childhood leukemia. ( 29574256 )
2018
9
Maternal residential pesticide use and risk of childhood leukemia in Costa Rica. ( 29658108 )
2018
10
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia &amp;amp; lymphoma study. ( 29728694 )
2018
11
Acid-suppressing Drugs and a Low 1 Level of Antithrombin as Risk Factors for L-Asparaginase-associated Pancreatitis: A Case-control Study in the Japan Association of Childhood Leukemia Study (JACLS). ( 29697579 )
2018
12
Living on a farm, contact with farm animals and pets, and childhood acute lymphoblastic leukemia: pooled and meta-analyses from the Childhood Leukemia International Consortium. ( 29663688 )
2018
13
Re: Kheifets et al. (2017): Residential magnetic fields exposure and childhood leukemia: a population-based case-control study in California. ( 29736896 )
2018
14
Advanced parental age as risk factor for childhood acute lymphoblastic leukemia: results from studies of the Childhood Leukemia International Consortium. ( 29761423 )
2018
15
SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy. ( 29683944 )
2018
16
Family interactions in childhood leukemia: an exploratory descriptive study. ( 29948395 )
2018
17
Radiation exposure from computerised tomography and risk of childhood leukemia: Finnish register-based case-control study of childhood leukemia (FRECCLE). ( 29976736 )
2018
18
Maternal consumption of coffee and tea during pregnancy and risk of childhood ALL: a pooled analysis from the childhood Leukemia International Consortium. ( 29600472 )
2018
19
Brain Connectivity and Cognitive Flexibility in Nonirradiated Adult Survivors of Childhood Leukemia. ( 29514304 )
2018
20
A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from TACL consortium. ( 29339403 )
2018
21
Changes in Oxidant Defense, Apoptosis, and Cognitive Abilities During Treatment for Childhood Leukemia. ( 29514461 )
2018
22
Neurocognitive Consequences of Childhood Leukemia and Its Treatment. ( 29398801 )
2018
23
Lower quality of life in young men after pediatric kidney transplantation when compared to healthy controls and survivors of childhood leukemia-a cross-sectional study. ( 28850735 )
2017
24
Gestational age and childhood leukemia: A meta-analysis of epidemiologic studies. ( 29099685 )
2017
25
Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia. ( 27726029 )
2017
26
Microstructure alterations in the Hypothalamus in cranially radiated Childhood Leukemia survivors but not in Craniopharyngioma patients unaffected by hypothalamic damage. ( 28502079 )
2017
27
Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in Pediatric Patients with Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia Consortium Study. ( 28396162 )
2017
28
Infectious Agents in Childhood Leukemia. ( 29157671 )
2017
29
Long-term Results of the Risk-adapted Treatment for Childhood B-Cell Acute Lymphoblastic Leukemia: Report From the Japan Association of Childhood Leukemia Study ALL-97 Trial. ( 28169879 )
2017
30
The Contribution of MMP-8 Promoter Genotypes to Childhood Leukemia. ( 29102926 )
2017
31
Geographical Distribution and Cluster Detection of Childhood Leukemia in the Metropolitan Area of Guadalajara, Mexico. ( 28613286 )
2017
32
Residential magnetic fields exposure and childhood leukemia: a population-based case-control study in California. ( 28900736 )
2017
33
50 Years Ago in The Journal of Pediatrics: Prevention and Management of Acute Hyperuricemia in Childhood Leukemia. ( 29173302 )
2017
34
Trends in childhood leukemia incidence over two decades from 1992 to 2013. ( 27778348 )
2017
35
Space-Time Clustering of Childhood Leukemia: Evidence of an Association with ETV6-RUNX1 (TEL-AML1) Fusion. ( 28129329 )
2017
36
Residential Proximity to Gasoline Stations and Risk of Childhood Leukemia. ( 27923798 )
2017
37
Contribution of Matrix Metalloproteinase-7 Genotypes to the Risk of Non-solid Tumor, Childhood Leukemia. ( 29187444 )
2017
38
Early vaccination protects against childhood leukemia: A systematic review and meta-analysis. ( 29167460 )
2017
39
Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL): Overview and introduction to the proceedings of the 2016 TACL investigator meeting. ( 29120691 )
2017
40
Clinical Presentation, Prognostic Factors, and Outcome in Neutropenic Enteropathy of Childhood Leukemia. ( 29293190 )
2017
41
Aberrant AML1 gene expression in the diagnosis of childhood leukemias not characterized by AML1-involved cytogenetic abnormalities. ( 28349830 )
2017
42
Possible role of pandemic AH1N1 swine flu virus in a childhood leukemia cluster. ( 28446785 )
2017
43
Comparative analyses of studies of childhood leukemia and magnetic fields, radon and gamma radiation. ( 28586320 )
2017
44
Immune Dysfunction After Completion of Childhood Leukemia Therapy. ( 27820131 )
2017
45
Brain structure, working memory and response inhibition in childhood leukemia survivors. ( 28239531 )
2017
46
Unconventional oil and gas development and risk of childhood leukemia: Assessing the evidence. ( 27783932 )
2017
47
Characterizing neurocognitive late effects in childhood leukemia survivors using a combination of neuropsychological and cognitive neuroscience measures. ( 29017430 )
2017
48
Novel agents for the treatment of childhood leukemia: an update. ( 28740405 )
2017
49
TACL'ing supportive care needs in pediatric early phase clinical trials for acute leukemia: A report from the therapeutic advances in childhood leukemia &amp;amp; lymphoma (TACL) consortium supportive care committee. ( 29190169 )
2017
50
Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia &amp;amp; Lymphoma (TACL) Consortium Biology Working Group. ( 29190164 )
2017

Variations for Childhood Leukemia

Expression for Childhood Leukemia

Search GEO for disease gene expression data for Childhood Leukemia.

Pathways for Childhood Leukemia

Pathways related to Childhood Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.97 NQO1 PBX1 RUNX1 TCF3
2 11.49 ETV6 KMT2A MLLT1 MLLT3 PBX1 RUNX1
3
Show member pathways
10.73 AKR1C3 NQO1 TP53

GO Terms for Childhood Leukemia

Cellular components related to Childhood Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.7 ARID5B EAF2 KMT2A MLLT1 MLLT3 PBX1
2 HFE-transferrin receptor complex GO:1990712 9.16 HFE TFRC
3 transcription elongation factor complex GO:0008023 8.8 EAF2 MLLT1 MLLT3
4 nucleus GO:0005634 10.1 ACTG1 AKR1C3 ARID5B EAF2 ETV6 KMT2A

Biological processes related to Childhood Leukemia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 9.9 ARID5B EAF2 ETV6 KMT2A MLLT1 MLLT3
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.87 EAF2 ETV6 KMT2A PBX1 RUNX1 TCF3
3 positive regulation of transcription, DNA-templated GO:0045893 9.73 EAF2 KMT2A MLLT3 RUNX1 TCF3 TP53
4 transcription, DNA-templated GO:0006351 9.7 ARID5B EAF2 ETV6 KMT2A MLLT1 MLLT3
5 protein-containing complex assembly GO:0065003 9.69 HFE KMT2A TP53
6 anterior/posterior pattern specification GO:0009952 9.63 KMT2A MLLT3 PBX1
7 regulation of hematopoietic stem cell differentiation GO:1902036 9.61 KMT2A RUNX1 TCF3
8 transcription elongation from RNA polymerase II promoter GO:0006368 9.58 EAF2 MLLT1 MLLT3
9 adrenal gland development GO:0030325 9.49 ARID5B PBX1
10 embryonic hemopoiesis GO:0035162 9.48 KMT2A PBX1
11 hematopoietic stem cell proliferation GO:0071425 9.37 ETV6 RUNX1
12 transcription by RNA polymerase II GO:0006366 9.23 EAF2 ETV6 KMT2A MLLT1 MLLT3 PBX1

Molecular functions related to Childhood Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.91 ARID5B ETV6 KMT2A MLLT1 PBX1 RUNX1
2 transcription regulatory region DNA binding GO:0044212 9.62 ARID5B KMT2A RUNX1 TP53
3 lysine-acetylated histone binding GO:0070577 9.37 KMT2A MLLT3
4 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.35 ARID5B EAF2 ETV6 PBX1 RUNX1
5 RNA polymerase II transcription factor activity, sequence-specific DNA binding GO:0000981 9.28 ARID5B ETV6 KMT2A MLLT1 MLLT3 PBX1
6 protein binding GO:0005515 10.11 ACTG1 ARID5B C1QC CYP1A1 EAF2 ETV6

Sources for Childhood Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....